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NOLL, B., ET AL.: Influence of Pacing Mode and Rate on Peripheral Levels of Atrial Natriuretic Peptide
(ANP). The effect of acute modifications of pacing mode and rate on plasma ANP levels was evaluated.
ANP was determined in ten resting patients with ODD pacemokers due to binodal disease or intermittent
second- and third-degree AV block. At 82/minute pacing rate the ANP plasma levels (normal range 2 to 30
fmol/mL] corresponded to those under AAI (4.05 ± 2.10fmol/mL} and DDD (4.18 ± 2.02 fmol/mL) pacing,
but increased significantly (P < 0.05} during WJ pacing {6.96 ± 3.70 fmol/mL). Acceleration of DDD
stimuJation frequency from 82 to n3/minutes led to significant increases of ANP levels by the factor of
three in all chosen AV delays. The lowest ANP plasma ieveis were measured of 175 msec AV delay under
82/minute pacing rate in DDD mode. Under 113/minutes the differences of ANP concentration after
variations of AV delays were less pronounced. The influences of aitered atriai pressure and tension on ANP
release are discussed to account for changes in ANP plasma ieveJs following different modes and rates of
pacemaker stimulation. (PACE, Vol. 12, November 1989}
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Introduction
The atria of the heart are important physio-
logical sites of volume regulation. Beside working
musculature and the specific conduction system,
myoendocrine cells are located there that synthe-
size and store the atrial natriuretic peptide
(ANP).' Increases of ANP plasma levels can be
elicited by atrial stretch caused by volume ex-
pansion, elevation of atrial pressure, and atrial
tachycardia.^"•'
The aim of the present study was to investi-
gate the acute influence of different pacing
modes, rates, and AV delays in patients with dual
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chamber pacemakers (DDD) on peripheral plasma
levels of ANP. This was of interest since AV con-
duction disturbances lead to elevated atrial blood
pressure. It was descrihed that in the atrial pulse
tracing of patients with third-degree AV block
"cannon" A waves occur when the atrium con-
tracts against a closed AV valve."^ Furthermore, it
was suggested that variations in AV synchrony
influence ANP plasma levels.^
Methods
Ten patients with DDD pacemakers (6 with
Biotronik Diplos 04/05, [Biotronik, Lake Oswego,
OR, USA] 4 with Intermedics Cosmos [Intermed-
ics. Inc., Freeport. TX, USA]) were examined be-
tween 8 and 11 o'clock AM. The mean age of the
patients was 65 years. None of them showed clin-
ical evidence of congestive heart failure, valvular
heart disease, or pulmonary disease. Three of
them were treated with digitalis glycosides. two
with nitrates, and none of them with diuretics.
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AAI us UUI, p<e.e5: DDD US W I , p<e.e5: AAI US DDD. p=n.s .
Figure 1. Mean absolute (lA) and relative (IB) ANP plasma levels during AAI, DDD. and WI
pacing at 82/minute (given are means ± SD).
The indications for pacemaker therapy were doc-
umented as intermittent second- and third-degree
AV biock or binodal disease in five patients, re-
spectively.
In resting patients, the pacemakers were pro-
grammed at a rate of 82 bpm and different AV
intervals (200. 175, 150, 125. 100, 50. and 15*
msec) were chosen (^impossible in the 4 patients
with Intermedics Cosmos pacemakers). Under
these conditions, the stimulation of atrium and
ventricle was performed exclusively by the pace-
makers. Same patients were examined 1 day later
using DDD stimulation at a rate of 113/minute
and 175, 150, 125. 100. and 50 msec AV delay. At
200 msec AV intervals, most patients displayed
ventricular combination systoles in the ECG trac-
ing. Therefore, we did not use this AV delay. At a
frequency of 113/minute. the pacemakers could
not be programmed in 15 msec AV delay.
The next day. ANP plasma concentrations of
these patients were examined under AAI, DDD
(175 msec AV delay) and VVI stimulation at 82/
minute pacing rate.
Ten minutes after switching to another AV
delay or changing the pacing mode, blood was
saved from an antecubital vein. Plasma ANP was
measured as previously described.^ In brief, blood
samples were collected on ice into EDTA tubes
containing 500 kU/mL of the protease inhibitor
aprotinin (Trasylol. Bayer AG, Leverkusen, FRG).
After centrifugation at 2000 g at 4°C for 30 min-
utes. ANP was extracted using Cl8-Sep-pak car-
tridges (Waters Associates. Milford, MA, USA),
Eluates were stored at -70°C until assay. ANP
was measured using a specific radioimmunoassay
method (Amersham. human a ANP [I 125] radio-
immunoassay system, code RPA.512).
Results are given as absolute ANP plasma
levels during the respective AV delays or pacing
modes. Relative changes in ANP concentration
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RELATIUE ANP PLASMA LEUELS AT DIFFEREMT PACING NODES
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Figure 1. Continued
were calculated in comparison to basal levels
which were assumed to be - 1.
Statistical analysis was performed using one-
way analysis of variance and Student's t-test for
repeated measurements. Differences at the 95%
level were considered significant. All values are
means ± standard deviation (SD).
Results
The mean absolute and relative ANP plasma
levels during AAI. DDD, and VVI pacing at 82/
minute are shown in Figure 1. In our resting pa-
tients. VVI stimulation caused a significant in-
crease of circulating ANP compared to DDD and
AAI pacing. There was no difference in ANP be-
tween AAI and DDD pacing mode. ANP levels
were also altered by changing the programmed
AV delay in DDD pacing (Table I).
At 82/minute pacing rate, lowest ANP
plasma concentration were measured at 175 msec
AV delay. Both extending and shortening the AV
delay caused an increase of ANP. At 15 msec AV
Table
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intervals, the elevation of ANP was statistically
significant compared to the others. Programming
this short AV delay led to hormone concentra-
tions comparable to those under VVI stimulation.
At 113/minute stimulation frequency, both
the mean plasma ANP levels (Fig. 2) as well as those
of the respective AV delays (Table II) were more
than threefold higher than under 82/minute.
The ANP level at a 50 msec AV delay was
above those resulting from all other AV delays. In
contrast to the results described above a definite
minimum of absolute or relative ANP plasma
levels at certain AV intervals could not be found
under 113/minute.
Discussion
Myoendocrine cells located in both atria and
ventricle of the heart synthesize the atrial natri-
uretic peptide and store it as a prohormone of 126
amino acids. The C-terminal part of 28 amino
acids contains the biologically active part of the
molecule.̂ •'̂  Once released. ANP has a half-life of
3 minutes and leads to increased glomerular fil-
tration, natriuresis, diuresis, and to an inhibition
of aldosterone secretion and suppression of vaso-
pressin release.^'^
Sensitive radioimmunoassay systems are
now available for routine ANP measurements.
Approximately 2 to 30 fmol/mL of this peptide
can be measured in human plasma of healthy in-
dividuals."'^" There is evidence for an increase of
ANP plasma concentrations with age in the litera-
ture, which is thought to mirror a compensatory
mechanism resulting from decreased tissue re-
sponses to ANP.^ However, the basal hormone
levels in our patients, who were 65-years-old on
an average, ranged from 3.5 to 17.7 fmol/mL and





Figure 2. Mean ANP plasma levels at 82/minute and n3/minu(e pacing rate (given are means
±SDJ.
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were, therefore, comparable to those values pre-
viously described in younger individuals. This
may be due to the lack of congestive heart failure
or pulmonary disease in our patients. These dis-
eases are often seen in aged patients and are
known to elevate ANP plasma levels.'^'^ How-
ever, the efficiency of the plasma extraction pro-
cedure used may be an important consideration.
Our sample purification method yields about 75%
recovery of atrial natriuretic peptide. This must
be taken into account when ANP concentrations
reported in tbe literature are compared with ours.
An increase of circulating ANP is caused by
atrial stretch or dilatation as well as frequent
atrial pacemaker stimulation or atrial fibrilla-
tion.^'^^'^ Furthermore, the pacing mode influ-
ences ANP secretion. Haufe and co-workers
found that right ventricular pacing led to a pacing
rate dependent increase of ANP plasma levels up
to 300%, whereas significant higher hormone
levels under AAI pacing occurred only at pacing
rates higher than 140/minute.^ The authors re-
ported a correlation between right atrial blood
pressure and plasma ANP concentrations. StangI
and co-authors described higher plasma ANP in
patients with third-degree AV block at rest and
under bicycle ergometry during VVI pacing at
70/minute compared to DDD pacing with 100
msec AV delay.^
Our data show that variations of AV delay
also influence peripheral ANP plasma levels.
Minimal ANP concentrations were detected at
82/minute under 175 msec AV delay. Both
shorter and longer AV intervals led to higher hor-
mone levels. This was discussed as being due tc
alterations of atrial pressure and tension.^^'^
From animal experiments, it was reported that
under conditions that allowed the atrial systole to
get closer to the mechanical ventricular systole,
atrial contractions against a closed AV valve oc-
curred. These lead to elevated atrial pressure
with blood regurgitation into the pulmonary
veins. This caused an enlargement of the left
atrial diameter.^"'" Furthermore, significant
changes in cardiac output due to slight AV inter-
val variations were reported from clinical obser-
vations.^^
At a 113/minute pacing rate, the differences
in ANP plasma levels caused by AV delay varia-
tions were less pronounced. This higher stimula-
tion rate led to a threefold increase of hormone
Table II.
ANP Plasma Levels During DDD Pacing at a Rate
AV Delay
[msec]
113/mlnute at Various AV Delays
Absolute ANP







































concentrations in all AV intervals. Therefore,
since only slight changes in ANP plasma levels
occurred after changing the programmed AV
delay these hormone levels could not be used to
define the most hemodynamically beneficial AV
interval in DDD pacing at this pacing rate.
Interestingly, there were no differences in
plasma ANP levels between AAI and DDD pacing.
It is obvious that pacemaker stimulation of tbe
right ventricle did not induce any relevant ANP
release.
There was a statistical difference in plasma
ANP between VVI and DDD pacing at 82/minute.
This result corroborates a previous report con-
cerning the lack of AV synchrony in VVI pacing
with occurrence of "cannon A waves" in the
atrial pressure tracings.^"'' The "pacemaker syn-
drome" is believed to be based on the latter
pathomechanism.^'^^ Until now, it is rather specu-
lative to hypothesize whether an increase of atrial
natriuretic peptide in VVI pacing may contribute
to this "pacemaker syndrome". In tbis context it
seems of some interest to evaluate ANP levels
after a prolonged pacing in the VVI mode. This is
not done in the present study, but is an important
matter for further research. The known direct
vasodilatory effect of ANP^̂  together with our re-
sults after acute stimulations offers at least a ratio-
nale to design such follow-up studies.
Acknowledgments: The data were presented at the toth
Annual Scientific Session of the North American Society of
Pacing and Electrophysiology 1989 in Toronto, Canada, and
have appeared in ahstracf form [PACE 1989; 12 (Pt. 1):672]. B.
Goke is a research fellow of the Deufsche Forschungsge-
meinschaft (DFG; Heisenherg program). We are grateful to I.
Muttschall for skillful technical assistance.




Needleman P, Greenwald |E. Atriopeptin: A car- 10,
diac hormone involved in fluid, electrolyte, and
blood-pressure homeostasis. N Engl ) Med 1986;
314:828-834. 11.
Crozier IG, Nicholls MG, Ikram H, et al. Relation
between left atrial diameter and plasma atrial na-
triuretic peptide, renin and vasopressin. Am }
Cardiol 1986; 58;1134-1136. 12.
Haufe MC, Weil J, Nafzger K, et al. Acute increase
in right atrial pressure by intracardiac stimulation 13.
releases atrial natriuretic peptide, Eur Heart J
1987; 8:277-281.
Craige E, Smith D. Heart sounds: Phonocardiogra-
phy; carotid, apex, and jugular venous pulse trac- 14,
ings; and systohc time intervals. In E Braunwald
(ed,): Heart Disease. Philadelphia, WB Saunders,
1988, pp, 41-64.
Stangl K, Weil J, Seitz K, et al. Influence of AV 15.
synchrony on the plasma levels of atrial natri-
uretic peptide (ANP) in patients with total AV
block, PACE 1987; 11:1176-1181, 16.
Riegger GAJ, Eisner D, Kiomer EP. et al. Atrial
natriuretic peptide in congestive heart failure in
the dog: Plasma levels, cyclic guanosine mono-
phosphate, ultrastructure of atrial myoendocrine 17.
cells, and hemodynamic, hormonal, and renal ef-
fects, Girculation 1988; 77(2):398-406.
Forsmann WG. Cardiac hormones. I. Review on
the morphology, biochemistry, and molecular bi- 18.
ology of the endocrine heart. Eur } Clin Invest
1986; 16:439-451.
De Bold AJ, Borenstein HB, Veress AT, et al. A
rapid and potent natriuretic response to intrave- 19.
nous injection of atrial extracts in rats. Life Sci
1981; 28:89-94,
Ohashi M. Fujio N, Nawata H, et al. High plasma
concentrations of human atrial natriuretic poly-
peptide in aged men, f Chn Endocr 1987; 64:81-85.
Pastan SO, Braunwald E, Renal disorders and
heart disease. In E Braunwald (ed.): Heart Disease.
Philadelphia, WB Saunders, 1988, pp. 1828-1847,
Anderson JV. Woodruff PWR, Bloom SR. The ef-
fect of treatment of congestive heart failure on
plasma atrial natriuretic peptide concentration, Br
Heart J 1988; 59:207-211,
Goetz KL. Physiology and pathophysiology of
atrial peptides. Am J Physiol 1988; 254:El-El5.
Matsubara H, Nishikawa M, Umeda Y, et al. The
role of atrial pressure in secreting atrial natri-
uretic polypeptides. Am Heart | 1987; 113:1457-
1463.
Roy D, Paillard D, Cassidy D, et al, Atrial natri-
uretic factor during atrial fibrillation and supra-
ventricular tachycardia, | Am Coll Cardiol 1987;
9:509-514.
Schiebinger RJ, Linden }, Effect of atrial contrac-
tion frequency on atrial natriuretic peptide secre-
tion. Am I Physiol 1986; 251:Hl095-Hl099.
Alicandri C, Fouad FM, Tarazi RC, et al. Three
cases of hypotension and syncope with ventricu-
lar pacing; possible role of atrial reflexes. Am J
Cardiol 1978; 42:137-142.
Faison EP, Siegl PKS. Morgan G, et al. Regional
vasorelaxant selectivity of atrial natriuretic factor
in isolated rabbit vessels. Life Sci 1985; 37:1073-
1079.
Naito M, Dreifus LS, Mardelli TJ, et al. Echocar-
diographic features of atrioventricular and ven-
triculoatrial conduction. Am } Cardiol 1980;
46:625-633,
Thormann J, Schlepper M. Hamodynamische
Auswirkungen kardialer Arrhythmien. In B
Liideritz (ed,): Handbuch der inneren Medizin,
Berlin-Heidelherg-New York: Springer, 1983, pp,
355-421.
1768 November 1989 PACE. Vol. 12

